Purified antineoplaston fractions and methods of treating...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

167/115, 167/232

A61K 35/22 (2006.01) A61K 31/195 (2006.01) A61K 31/445 (2006.01) C07K 4/12 (2006.01) C07K 14/47 (2006.01) A61K 38/00 (2006.01)

Patent

CA 1188218

Abstract Disclosed is a pharmaceutical composition for inhibiting growth of neoplastic cells in a host having neoplastic disease which composition contains as an active ingredient a growth inhibiting substance having at least one small-size peptide chemical structure having 2 to 9 amino acid residues, which substance occurs as an antineoplastic ingredient in urine, and has a molecular weight of less than 2,000, or pharmaceuti- cally acceptable addition salts thereof. The invention also pertains to a process of obtaining from a volume of urine a fraction having antineoplastic activity, comprising: separating from the urine matter having a molecular weight greater than 5,000; fractionating the urine to obtain a peptide fraction having antineoplastic activity, the peptides having from 2 to 9 amino acid residues; and recovering the peptide fraction having antineoplastic activity.

403789

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Purified antineoplaston fractions and methods of treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Purified antineoplaston fractions and methods of treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purified antineoplaston fractions and methods of treating... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1276131

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.